BioCentury | Mar 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Steroid sulfatase (STS) Mouse studies suggest hepatic STS overexpression could help treat obesity and diabetes. In genetic- or high-fat diet-induced female mouse...
BioCentury | Jan 24, 2011
Company News

CK Life Sciences, Wex deal

...Wex shareholders accept an increased offer from CK's Pharmagesic Inc. subsidiary for the 11.3% of Wex's...
...an unsolicited offer for C$0.13 per share. The new price is a 40% premium to Wex's...
...of C$0.10 on July 9, the last trading day before the original deal was announced. Wex's...
BioCentury | Oct 4, 2010
Clinical News

Tetrodotoxin: Phase III ongoing

...evaluable patients. The review was based on safety and efficacy data in 60 evaluable patients. Wex...
...this month. Wex plans to continue enrollment in the trial until a decision is made. Wex Pharmaceuticals Inc....
BioCentury | Jul 19, 2010
Company News

CK Life Sciences, Wex deal

...CK's Pharmagesic Inc. subsidiary made an unsolicited offer for the 11.3% of Wex's restricted voting shares...
...on 442.4 million shares outstanding on March 31. The price is a 30% premium to Wex's...
...was announced. Wex said it has formed an independent directors committee to review the offer. Wex's...
BioCentury | Feb 1, 2010
Finance

Regulatory milestones

...Zentaris, which lost C$0.03 to C$0.92 in Toronto and fell $0.08 to $0.85 on NASDAQ. Wex Pharmaceuticals Inc....
BioCentury | Feb 1, 2010
Financial News

Wex completes rights offering

Wex Pharmaceuticals Inc. (TSX:WXI), Vancouver, B.C. Business: Neurology, Generics Date completed: 1/26/10 Type: Rights offering Raised: C$34.5 million (US$32.6 million) Shares: 265.5 million Price: C$0.13 Shares after offering: 442.5 million Investors: Existing investors Note: Shareholders...
BioCentury | Jan 28, 2010
Financial News

Wex raises $32.6 million

...announced rights offering. Shareholders were eligible to purchase one-and-a-half shares for each existing share held. Wex's...
...testing to treat cancer-related pain. Tectin is a sodium channel blocker derived from puffer fish. Wex...
BioCentury | Dec 7, 2009
Financial News

Wex proposes rights offering

Wex Pharmaceuticals Inc. (TSX:WXI), Vancouver, B.C. Business: Neurology, Generics Date announced: 11/27/09 Type: Rights offering To be raised: Up to C$34.5 million ($32.7 million) Shares: 265.5 million Shares outstanding prior: 177 million Price prior: C$0.19...
BioCentury | Dec 7, 2009
Finance

Ebb & Flow

...a share in an offering underwritten by Goldman Sachs; Merrill Lynch; JPMorgan; and Morgan Stanley. Wex Pharmaceuticals Inc....
BioCentury | Dec 1, 2009
Financial News

Wex planning offering

...million shares at C$0.13 in a rights offering. The price is a 32% discount to Wex's...
...was announced. Shareholders will be eligible to purchase one-and-a-half shares for each existing share held. Wex's...
...data are expected next quarter. Tectin is a sodium channel blocker derived from puffer fish. Wex...
Items per page:
1 - 10 of 15
BioCentury | Mar 6, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Steroid sulfatase (STS) Mouse studies suggest hepatic STS overexpression could help treat obesity and diabetes. In genetic- or high-fat diet-induced female mouse...
BioCentury | Jan 24, 2011
Company News

CK Life Sciences, Wex deal

...Wex shareholders accept an increased offer from CK's Pharmagesic Inc. subsidiary for the 11.3% of Wex's...
...an unsolicited offer for C$0.13 per share. The new price is a 40% premium to Wex's...
...of C$0.10 on July 9, the last trading day before the original deal was announced. Wex's...
BioCentury | Oct 4, 2010
Clinical News

Tetrodotoxin: Phase III ongoing

...evaluable patients. The review was based on safety and efficacy data in 60 evaluable patients. Wex...
...this month. Wex plans to continue enrollment in the trial until a decision is made. Wex Pharmaceuticals Inc....
BioCentury | Jul 19, 2010
Company News

CK Life Sciences, Wex deal

...CK's Pharmagesic Inc. subsidiary made an unsolicited offer for the 11.3% of Wex's restricted voting shares...
...on 442.4 million shares outstanding on March 31. The price is a 30% premium to Wex's...
...was announced. Wex said it has formed an independent directors committee to review the offer. Wex's...
BioCentury | Feb 1, 2010
Finance

Regulatory milestones

...Zentaris, which lost C$0.03 to C$0.92 in Toronto and fell $0.08 to $0.85 on NASDAQ. Wex Pharmaceuticals Inc....
BioCentury | Feb 1, 2010
Financial News

Wex completes rights offering

Wex Pharmaceuticals Inc. (TSX:WXI), Vancouver, B.C. Business: Neurology, Generics Date completed: 1/26/10 Type: Rights offering Raised: C$34.5 million (US$32.6 million) Shares: 265.5 million Price: C$0.13 Shares after offering: 442.5 million Investors: Existing investors Note: Shareholders...
BioCentury | Jan 28, 2010
Financial News

Wex raises $32.6 million

...announced rights offering. Shareholders were eligible to purchase one-and-a-half shares for each existing share held. Wex's...
...testing to treat cancer-related pain. Tectin is a sodium channel blocker derived from puffer fish. Wex...
BioCentury | Dec 7, 2009
Financial News

Wex proposes rights offering

Wex Pharmaceuticals Inc. (TSX:WXI), Vancouver, B.C. Business: Neurology, Generics Date announced: 11/27/09 Type: Rights offering To be raised: Up to C$34.5 million ($32.7 million) Shares: 265.5 million Shares outstanding prior: 177 million Price prior: C$0.19...
BioCentury | Dec 7, 2009
Finance

Ebb & Flow

...a share in an offering underwritten by Goldman Sachs; Merrill Lynch; JPMorgan; and Morgan Stanley. Wex Pharmaceuticals Inc....
BioCentury | Dec 1, 2009
Financial News

Wex planning offering

...million shares at C$0.13 in a rights offering. The price is a 32% discount to Wex's...
...was announced. Shareholders will be eligible to purchase one-and-a-half shares for each existing share held. Wex's...
...data are expected next quarter. Tectin is a sodium channel blocker derived from puffer fish. Wex...
Items per page:
1 - 10 of 15